Eisai Forecasts 63% Leqembi Revenue Surge to JPY 143.5B in FY2026
Event summary
- Eisai projects Leqembi revenue to reach JPY 143.5 billion in fiscal year 2026, a 63% increase from the previous year.
- BioArctic stands to earn approximately SEK 880 million in royalties from Leqembi sales during the same period.
- Leqembi is approved in 53 countries and under regulatory review in 6 additional countries.
- BioArctic and Eisai are preparing for joint commercialization of Leqembi in the Nordic region.
- Leqembi's subcutaneous formulation is under priority review in the US and China.
The big picture
Eisai's aggressive revenue forecast for Leqembi underscores the growing market for Alzheimer's treatments, particularly as the drug gains broader regulatory approval and commercialization momentum. BioArctic's royalty model positions it to benefit from Eisai's success, though its ability to scale in the Nordic region will be a key test of its strategic partnership. The biopharmaceutical sector continues to prioritize neurodegenerative disease treatments, with Leqembi emerging as a potential blockbuster in this space.
What we're watching
- Regulatory Approvals
- The pace at which Leqembi's subcutaneous formulation gains approval in key markets like the US and China will impact BioArctic's royalty stream.
- Commercialization Strategy
- Whether BioArctic and Eisai can successfully execute joint commercialization in the Nordic region will be critical for revenue growth.
- Clinical Development
- Progress in ongoing clinical studies, such as AHEAD 3-45 and Tau NexGen, could open new indications and expand Leqembi's market potential.
Related topics